Overview of 2027 Medicare Advantage Updates
The Centers for Medicare and Medicaid Services recently released transformative policy proposals for Medicare Advantage and Part D programs affecting contract year 2027. These sweeping changes represent the most significant Medicare program modernization in years, addressing quality measurement, beneficiary protections, and prescription drug benefits while codifying Inflation Reduction Act provisions.
The proposed rule introduces major revisions across multiple program areas including Star Ratings methodology, risk adjustment modeling, marketing regulations, and special enrollment periods. Healthcare stakeholders face critical deadlines to review these complex updates and submit feedback before final implementation later this year.
Star Ratings System Overhaul
Eliminating Performance Measures
CMS proposes removing twelve administrative performance measures from the Star Ratings system beginning with the 2027 measurement year. These measures consistently showed high performance across plans, prompting their elimination to streamline quality assessment and reduce administrative burden on health plans.
The removed measures include call center availability indicators, plan finder price accuracy metrics, appeals processing timelines, and care management assessments. This reduction shifts focus toward outcome-based measures delivering greater beneficiary value rather than process-focused administrative metrics.
Health Equity Index Reversal
In a significant policy reversal, CMS proposes abandoning the previously finalized Health Equity Index reward scheduled for 2027 Star Ratings. Instead, the agency will retain the existing historical reward factor, preferring to incentivize clinical care improvements across all beneficiary populations rather than targeting specific demographic groups.
This change alone drives substantial financial implications, with CMS projecting increased Medicare spending reaching $13.8 billion between 2027 and 2036. The most significant spending increases occur in 2028 and 2029, when quality bonus payments tied to revised ratings generate $5.0 billion and $2.3 billion increases respectively.
Inflation Reduction Act Implementation
Part D Benefit Design Changes
The proposed rule codifies critical Inflation Reduction Act reforms reshaping Part D prescription drug coverage. These changes eliminate the coverage gap phase, lower out-of-pocket spending thresholds, remove catastrophic phase cost sharing, and implement the Manufacturer Discount Program.
Beneficiaries will experience more predictable prescription costs with simplified benefit structures replacing the complex multi-phase coverage model. The standardized benefit parameters provide clearer cost expectations while reducing administrative complexity for plan sponsors managing prescription benefits.
Risk Adjustment Model Transformation
Beyond Traditional Diagnosis Codes
CMS explores modernizing the Hierarchical Condition Category risk adjustment model by incorporating encounter data patterns, clinical markers, laboratory values, and prescription activity alongside traditional diagnosis codes. This transformation addresses industry concerns that current HCC-capture improvement efforts consume significant resources without necessarily improving health outcomes.
The proposed risk model updates, combined with technical normalization adjustments, project reducing risk-adjusted payments by $15.22 billion for 2027. These substantial revisions will likely generate extensive stakeholder engagement requesting phased implementation to minimize financial disruption.
Enhanced Enrollment and Marketing Flexibility
Special Enrollment Period Expansion
The proposed rule modifies special enrollment periods triggered when beneficiaries’ providers leave plan networks. The updated policy eliminates requirements that network changes be deemed “significant” before triggering enrollment rights, automatically qualifying affected beneficiaries for plan switching opportunities.
Marketing Regulation Relief
CMS proposes reducing restrictions on beneficiary outreach activities and third-party marketing organizations. These changes include revising disclaimer timing requirements, removing limitations on educational event follow-up marketing, and streamlining scope of appointment procedures. The marketing updates take effect October 1, 2026, when 2027 plan year marketing begins.
Financial Impact on Medicare Spending
The combined policy changes project increasing Medicare expenditures by nearly $14 billion over the next decade. Payment increases concentrate in early implementation years, primarily driven by higher quality bonus payments resulting from revised Star Ratings methodology and retained historical reward factors.
Individual plan impacts vary significantly based on geographic location, 2026 Star Rating performance, and enrolled population health status. The industry-wide averages mask substantial variation requiring detailed plan-specific analysis for accurate financial projections.
Timeline and Stakeholder Engagement
Critical Comment Deadlines
Stakeholders must submit comments on the proposed rule by late February 2026, with CMS finalizing policies by early April. The Advance Notice for payment rates follows similar timelines, allowing plans to incorporate finalized policies into June 2026 bid submissions for contract year 2027.
Strategic Preparation Requirements
Healthcare organizations should immediately assess how proposed changes affect quality bonus payments, risk adjustment revenue, health equity initiatives, and operational workflows. Early engagement in the comment process enables stakeholders to shape final regulations while preparing internal systems for implementation beginning October 2026.
